About SynDevRx

Intellectual Property

SynDevRx has developed a new class of polymeric drugs based on our proprietary drug release technology.  Polymeric drugs have a long history, but like all new technologies, they require decades of perfecting before a successful drug will emerge. In addition to claims to this overlooked aspect of polymeric drug development, SynDevRx also has new composition of matter IP on all its compounds.

For more information or to inquire about licensing our technology, please contact us.

NB: SynDevRx is not affiliated with Children's Hospital Boston.